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INTRODUCTION
Shock resulting from hemorrhage induces life-threaten-
ing ischemic injuries in organs as well as tissues. This dam-
age occurs during the resuscitation period, when neutrophils
become active and inflammatory cytokines increase in both
hemorrhagic shock and systemic inflammation (i.e. burn,
acute pancreatitis, sepsis). These systemic metabolic changes
can lead to acute respiratory distress syndrome and microis-
chemia of the liver, and can impair functions of the kidney,
heart and brain. Multiple organ failure is the leading cause
of mortality after hemorrhagic shock (1-3). 
Levels of interleukin-6 (IL-6), tumor necrosis factor alpha
(TNF-a) and polymorphonuclear leukocyte elastase (PMNE)
begin to increase in early inflammation, stimulating various
tissues and organs and leading to a systemic inflammatory
response. Riedemann et al. (4) revealed protective effects of
IL-6 blockade in sepsis. 
Ulinastatin, a glycoprotein with a molecular weight of
67,000 daltons derived from human urine, has anti-inflam-
matory activity which may suppress PMNE, TNF-a, IL-6,
IL-8 (5-8). In animal studies, the effects of ulinastatin on arti-
ficially induced hemorrhagic shock have been reported (8, 9),
but studies about inflammatory cytokines or PMNE and clin-
ical trials of hemorrhagic shock in humans have not been
reported. The purpose of this study was to investigate the
anti-inflammatory effects of ulinastatin on proinflammatory
cytokines and PMNE in trauma patients suffering from hem-
orrhagic shock.
MATERIALS AND METHODS
Subjects
We conducted a randomized, controlled trial with a sam-
ple of 19 adult patients who were admitted to the emergen-
cy department at our hospital for trauma from June 2006 to
October 2006. All enrolled patients suffered from traumatic
hemorrhagic shock, arrived within six hours after an accident,
and were 18 yr of age or older. 
Patients with documented preexisting heart failure, chron-
ic renal failure, liver cirrhosis or chronic obstructive pulmo-
nary disease were excluded. Other exclusion criteria includ-
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The Anti-Inflammatory Effects of Ulinastatin in Trauma Patients with
Hemorrhagic Shock 
We investigated the use of ulinastatin in association with the suppression of poly-
morphonuclear leukocyte elastase (PMNE), tumor necrosis factor alpha (TNF-a)
and interleukin 6 (IL-6), and its effects on the prognosis of patients with traumatic
hemorrhagic shock. Nineteen patients who visited the emergency department for
traumatic hemorrhagic shock were enrolled. Eleven patients were randomly select-
ed to receive a total of 300,000 IU of ulinastatin. Measurements of serum PMNE,
TNF-a and IL-6 were taken before ulinastatin treatment at 24 hr, two days, three
days, and seven days after admission. We compared the Systemic Inflammatory
Response Syndrome scores, Multiple Organ Dysfunction Syndrome scores and
Acute Physiology, age, Chronic Health Evaluation III scores of the control and uli-
nastatin groups. There were no significant differences in baseline values, laborato-
ry data, treatment or mortality between the two groups. The serum PMNE levels in
the ulinastatin group were lower than in the control group on the second hospital-
ized day. Serum TNF-a and IL-6 levels in the ulinastatin group decreased 24 hr
after admission but had no significance. It is suggested that ulinastatin treatment
could decrease the serum PMNE levels in trauma patients with hemorrhagic shock
at 48 hr after treatment.
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ed cardiopulmonary resuscitation and severe brain injury,
which was the main cause of death or morbidity. The enrolled
patients were randomly divided into two groups, with pati-
ents admitted on odd numbered days assigned to the ulinas-
tatin group and patients who were admitted on even num-
bered days assigned to the control group. Our study followed
the guidelines of the Institutional Review Board of Wonju
Christian Hospital, Yonsei University Wonju College of
Medicine (No, CR 106072). 
Administration of ulinastatin 
Ulinastatin was administrated to enrolled patients receiv-
ing blood transfusions and fluids immediately after diagno-
sis of hemorrhagic shock. Ulinastatin is commercially known
as Ulistin
� (Ulinastatin 100,000 IU/2 mL, Han Lim Pharm.
Co. Ltd, Seoul, Korea). The ulinastatin group received 100,000
IU of ulinastatin with 100 mL of normal saline for duration
of 30 min at a time, every eight hours, three times for a total
of 300,000 IU of ulinastatin over 24 hr of treatment.
Measurements of serum TNF-a, IL-6 and PMNE 
In the ulinastatin group, plasma concentrations of PMNE,
IL-6 and TNF-a were measured before injection of ulinas-
tatin, and at 24 hr, two, three, and seven days after injection.
In the control group, plasma concentrations of PMNE, IL-6
and TNF-a were measured upon admission to the emergen-
cy room (ER), and at 24 hr, two, three, and seven days after
admission. After centrifuging patient blood samples, the
serum was stored in a freezer and then dissolved for Enzyme-
Linked Immunosorbent Assay (ELISA; PhDTM System, Bio-
Rad, Hercules, CA, USA).
Serum PMNE was measured in terms of the concentration
of PMNE-a1-antitrypsin complex using a PMNE/a1-pro-
teinase inhibitor complex ELISA kit (Calbiochem
�, EMD
Biosciences, Inc., Darmstadt, Germany). Serum IL-6 was mea-
sured using a Human IL-6 immunoassay kit (Quantikine
�,
R&D Systems, Inc., Minneapolis, MN, USA). Serum TNF-a
was measured using a Human TNF-a/TNFSF1A immunoas-
say kit (Quantikine
�, R&D Systems). 
Analysis of results
Upon admission and at 48 hr after admission to the ER, the
Systemic Inflammatory Response Syndrome (SIRS) score, the
Multiple Organ Dysfunction Syndrome (MODS) score, the
Acute Physiology, Age, Chronic Health Evaluation (APACHE)
III, transfusion amounts, cause of death and the duration of
ICU admission of the control group and the ulinastatin group
were compared (Fig. 1).
Statistical analysis
Data are reported as mean±standard deviation. Statistical
analyses were performed with the Mann-Whitney U-test,
Pearson’s chi-square test for demographic data, and the Wil-
coxon test for comparison between the SIRS score, the MODS
score and the APACHE III score within the same group. Data
were summarized and coded into a software program (SPSS
v 13.0 for Windows, SPSS Inc., Chicago, IL, USA). P values
of <0.05 was considered statistically significant.
RESULTS
Demographic data for the patients
The control group consisted of eight patients (five males,
mean age 48.0±17.1 yr), and the ulinastatin group included
eleven patients (eight males, mean age 48.7±11.1 yr). There
were no significant differences in the two groups (P>0.05).
Regarding the injury mechanism, eight were traffic accidents,
three motorcycle accidents, five falls, one stabbing injury, one
cultivator accident and one collision by rock. The Injury Severi-
ty Scores (ISS) for the two groups were 27.1±22.5 and 20.6
Fig. 1. The study design.
GCS, Glascow coma scale; CPR, cardiopulmonary
resuscitation; COPD, chronic obstructive pulmonary
disease; TNF, tumor necrosis factor; IL, interleukin;
PMNE, polymorphonuclear leukocyte elastase; SIRS,
systemic inflammatory response syndrome; MODS,
multiple organ dysfunction syndrome; APACHE, acute
physiology, age, chronic health evaluation.
Trauma with hemorrhagic shock
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Severe brain injury (GCS <9)
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Liver cirrhosis Before injection
After 24 hours
After 2 days
After 3 days
After 7 days
Control group
(n=11)
TNF-a, IL-6, PMNE
SIRS score, MODS score,
APACHE III
Transfusion, admission 
duration, mortality, cause 
of death
Ulinastatin group (n=8)
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±11.6, respectively (P=0.901). The Revised Trauma Scores
(RTS) were 10.4±1.9 and 10.3±1.8, respectively (P=0.858).
None of these differences were significant (Table 1).
Serum TNF-a levels
White blood cell counts, neutrophil counts, hemoglobin,
pH, base excess and lactate were not significantly different bet-
ween the control and ulinastatin groups (P>0.05) (Table 2).
Serum TNF-a concentrations increased up to the third day
of hospitalization in the control group and decreased there-
after such that by the seventh day, concentrations were lower
than the initial concentrations obtained. Compared to the
baseline level, the serum TNF-a levels of 1st, 2nd, 3rd, and
7th days were lower within the ulinastatin group. There were
no significant differences between the mean concentrations of
serum TNF-a in the control and ulinastatin groups (Fig. 2). 
Serum IL-6 levels
In the ulinastatin group, the serum concentration of IL-6
was 141.77±113.59 pg/mL at baseline and decreased to
ISS, injury severity score; RTS, revised trauma score.
Characteristics
Control group
(n=8)
Ulinastatin group
(n=11)
P value
Age (yr) 48.0±17.1 48.7±11.1 1.000
Sex (M:F) 5/3 8/3 0.636
Injury mechanism 0.040
Pedestrian 2 1
Driver 0 1
Passenger 1 3
Motorcycle 3 0
Fall 0 5
Stab injury 0 1
Other 2 0
ISS 27.1±22.5 20.6±11.6 0.901
RTS 10.4±1.9 10.3±1.8 0.858
Table 1. Demographic data of enrolled patients
Parameters
Control group
(n=8)
Ulinastatin 
group (n=11)
P value
At admission
pH 7.42±0.72 7.35±0.15 0.265
Base excess (mM/L) -6.1±3.4 -8.2±5.2 0.364
Lactate (mM/L) 4.1±2.5 5.4±3.1 0.600
WBC (10
9/L) 22.4±5.8 22.4±8.1 0.934
Neutrophil (10
9/L) 18.3±5.9 17.9±7.8 0.741
Hemoglobin (g/dL) 10.6±2.4 10.7±3.2 0.934
At 24 hr after admission
pH 7.40±0.06 7.29±0.35 0.733
Base excess (mM/L) -2.1±2.7 -4.7±14.5 0.435
Lactate (mM/L) 2.6±2.6 3.7±3.3 0.425
WBC (10
9/L) 11.6±4.1 8.8±2.1 0.241
Neutrophil (10
9/L) 9.7±3.7 6.6±3.7 0.257
Hemoglobin (g/dL) 10.9±1.5 9.5±2.4 0.434
At two days after admission
pH 7.42±0.03 7.44±0.06 0.699
Base excess (mM/L) 0.1±1.5 0.9±3.4 0.606
Lactate (mM/L) 0.7±0.2 1.4±0.7 0.134
WBC (10
9/L) 10.4±3.5 9.2±2.7 0.562
Neutrophil (10
9/L) 8.5±3.8 7.5±1.2 1.000
Hemoglobin (g/dL) 9.3±0.9 9.3±0.9 0.816
At three days after admission
pH 7.42±0.03 7.41±0.04 0.698
Base excess (mM/L) 0.2±0.8 -0.63±3.19 0.794
Lactate (mM/L) 0.8±0.3 1.0±0.9 0.724
WBC (10
9/L) 8.2±2.9 8.3±1.6 0.563
Neutrophil (10
9/L) 6.5±3.1 6.8±1.5 0.465
Hemoglobin (g/dL) 9.4±1.1 9.1±0.9 0.353
At seven days after admission
pH 7.45±0.05 7.46±0.03 0.721
Base excess (mM/L) 2.4±2.9 1.4±2.2 0.471
Lactate (mM/L) 0.9±0.5 1.1±0.7 1.000
WBC (10
9/L) 10.2±3.5 9.8±5.4 0.655
Neutrophil (10
9/L) 7.4±3.6 7.7±3.1 0.732
Hemoglobin (g/dL) 10.5±1.1 10.3±1.4 0.654
Table 2. Comparison of laboratory data between the control
group and the ulinastatin group
WBC, white blood cell.
Fig. 2. (A) Effects of ulinastatin on serum TNF-a levels. (B) Changes in serum TNF-a levels after admission. HD0 means before injection of
ulinastatin. 
HD, hospitalized day.
S
e
r
u
m
 
T
N
F
-
a
(
p
g
/
m
L
)
25
20
15
10
5
0
HD0 HD1 HD2 HD3 HD7
Control group
Ulinastatin group
Control group
Ulinastatin group
A
S
e
r
u
m
 
T
N
F
-
a
(
p
g
/
m
L
)
10
8
6
4
2
0
-2
HD1 HD2 HD3 HD7 BThe Anti-Inflammatory Effects of Ulinastatin in Trauma Patients with Hemorrhagic Shock  131
52.82±29.68 pg/mL at 24 hr. The control group showed
an increase in serum IL-6 from 78.31±52.95 pg/mL at base-
line to 100.70±42.57 pg/mL at 24 hr. Although the IL-6
level of the ulinastatin group decreased more at HD1 than
that of the control group, there was no significant difference
(P>0.05) (Fig. 3).
Serum PMNE levels
The mean concentration of serum PMNE in the control
group increased continuously and was 11.58±5.57 ng/mL
on the second day of hospitalization. In the ulinastatin group,
serum PMNE also increased showing a small difference and
lower average. The mean plasma concentration of PMNE on
the second hospital day in the ulinastatin group was 4.33±
1.21 ng/mL, which was significantly lower than that of the
control group (P=0.019). 
The difference between the second hospitalized day and the
day of admission was statistically significant between two
groups (P=0.045) (Fig. 4)
Transfusion, treatment and mortality 
Within the 24 hr after admission to ER, the total transfu-
sion amounts of packed red blood cells, fresh frozen plasma,
and platelet concentration were not different between the two
groups (P>0.05). Within the control group, six of the eight
patients underwent an operation, one had conservative treat-
ment, and one patient died of hemorrhagic shock. In the uli-
nastatin group, six patients were treated conservatively and
five underwent operations. Two patients died: one of hem-
orrhagic shock and the other of multiple organ dysfunction
syndrome (Table 3). The treatment modalities in both groups
were not significantly different (P=0.117).
SIRS scores, MODS scores and APACHE III values 
In the ulinastatin group, the SIRS scores and APACHE III
values decreased significantly over 48 hr (2.3±0.9 vs. 0.8±
0.9, P=0.03; 42.7±28.6 vs. 24.9±23.8, P=0.02). MODS
scores decreased after 48 hr of admission, but there was no
difference between the treated and control groups (4.0±3.7
vs. 2.3±3.2, P=0.10). In the control group, SIRS and AP-
ACHE III scores decreased as well (2.8±1.0 vs. 0.6±0.8,
P=0.03; 45.0±28.2 vs. 16.9±13.1, P=0.02). However,
MODS scores remained stable (2.3±1.5 vs. 2.5±2.3, P=
0.59) (Table 4).
The means of SIRS, MODS, and APACHE III scores were
Fig. 3. (A) Effects of ulinastatin on serum IL-6 levels. (B) Changes in serum IL-6 levels after admission. HD0 means before infusion of uli-
nastatin.
HD, hospitalized day.
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Fig. 4. (A) Effects of ulinastatin on serum PMNE levels. (B) Changes in serum PMNE levels after admission. HD0 means before infusion of
ulinastatin. 
HD, hospitalized day.
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not significantly different between the two groups (Table 5).
DISCUSSION
One hundred years ago it was reported that human urine
had the capacity to inhibit trypsin (10). In 1955, the protein
responsible for the antitrypsin activity of urine, bikunin, was
isolated (10). One main function of bikunin is to inhibit ser-
ine protease, especially elastase, and to suppress neutrophils,
lymphocytes and macrophages increased by infection and
inflammation (11). Now commonly known as ulinastatin,
this urinary trypsin inhibitor inhibits cell apoptosis by free
radicals and lipid peroxidation in renal ischemia-reperfusion
injuries and has a suppressive effect against mitochondrial
injury (8). 
The effect of ulinastatin is dose-dependent (6, 12, 13). In
this study, 100,000 IU, three times per day (total 300,000 IU)
was administered as this is the recommended dosage for acute
circulatory failure. This is comparable to the 50,000 IU/kg
administered in canine experiments (9, 14), and 1,500,000
IU over a period of five days administered in clinical studies
(7, 15). In Japan, ulinastatin 6,000 IU/kg is considered as the
maximum safe dose (16). Although the possible side effects
of ulinastatin include nausea, vomiting and hypersensitivity
reactions, we did not observe any of these side effects in our
sample, nor have they been observed in others. In most ani-
mal studies, ulinastatin was administered before the induc-
tion of hemorrhagic shock or septic shock and in clinical tri-
als, before laparotomy or blood transfusion (5, 9, 14). In the
present study, ulinastatin was prescribed only after diagno-
sis of traumatic hemorrhagic shock.
We examined levels of serum TNF-a, IL-6, PMNE as in-
flammatory mediators associated with hemorrhagic shock.
Serum TNF-a is secreted by activated macrophages, stimu-
lating other inflammatory cytokines and bringing inflamma-
tory cells to tissues (17). IL-6 is secreted from the cells by an
early inflammatory reaction. In a rat model, trauma-induced
hemorrhagic shock led to increased plasma levels of the liver
enzyme, alanine aminotransferase (ALT), a marker of liver
injury, showing a significant correlation with IL-6 (18). Wit-
Parameters
Control group
(n=8)
Ulinastatin 
group (n=11)
P value
In 24 hr transfusion
pRBC 5.0±5.1 9.3±9.8 0.376
FFP 0.8±1.5 2.9±3.3 0.089
PC 0 2.2±3.7 0.117
Total transfusion
pRBC 7.9±8.3 11.6±11.2 0.430
FFP 3.8±9.1 3.4±3.4 0.137
PC 0 2.9±4.0 0.062
Treatment 0.117
Conservation 1 6
Operation 6 5
Moribound discharge 1 0
ICU admission days 12.0±19.2 5.8±6.3 0.787
Result 0.644
Discharge alive 6 6
Transfer 1 3
Death 1 2
Cause of death 0.672
Hypovolemia 1 1
MOF 0 1
Table 3. Transfusion, treatment modality and final results bet-
ween the control group and the ulinastatin group
pRBC, packed red blood cells; FFP, fresh frozen plasma; PC, platelet
concentrate, ICU, intensive care unit; MOF, multiple organ failure.
Parameters
At study 
entry
48 hr after 
admission
P value
Control group (n=8)
SIRS score  2.8±1.0 0.6±0.8 0.026
MODS score  2.3±1.5 2.5±2.3 0.596
APACHE III  45.0±28.2 16.9±13.1 0.018
Ulinastatin group (n=11)
SIRS score 2.3±0.9 0.8±0.9 0.026
MODS score 4.0±3.7 2.3±3.2 0.102
APACHE III 42.7±28.6 24.9±23.8 0.017
Table 4. SIRS score, MODS score and APACHE III score 48 hr
after admission
SIRS, systemic inflammatory response syndrome; MODS, multiple organ
dysfunction syndrome; APACHE, acute physiology, age, chronic health
evaluation.
Parameters
Control group
(n=8)
Ulinastatin  
group (n=11)
P value
At admission
SIRS score 2.8±1.0 2.3±0.9 0.224
MODS score 2.3±1.5 4.0±3.7 0.530
APACHE III 45.0±28.2 42.7±28.6 0.563
At two days after admission
SIRS score 0.6±0.8 0.8±0.9 0.702
MODS score 2.5±2.3 2.3±3.2 0.610
APACHE III 16.9±13.1 24.9±23.8 0.451
At three days after admission
SIRS score 0.3±0.5 0.3±0.5 1.000
MODS score 1.8±1.3 1.9±1.6 1.000
APACHE III 18.0±17.9 15.3±9.1 0.886
At seven days after admission
SIRS score 0.4±0.8 1.0±1.0 0.250
MODS score 1.0±1.1 1.7±1.7 0.455
APACHE III 19.5±16.3 17.4±14.5 0.886
Table 5. Comparison of SIRS score, MODS score and APACHE
III score between the control group and the ulinastatin group
SIRS, systemic inflammatory response syndrome; MODS, multiple organ
dysfunction syndrome; APACHE, acute physiology, age, chronic health
evaluation.The Anti-Inflammatory Effects of Ulinastatin in Trauma Patients with Hemorrhagic Shock  133
thaut et al. (19) reported that serum IL-6 values in septic shock
were 150 times higher than those of controls, and conclud-
ed therefore that IL-6 was the main cytokine of infection and
inflammation. Neutrophils secrete PMNE when inflamma-
tion occurs, which can injure every tissue and organ (20, 21).
Levels of proteases such as elastase are typically increased
in cases of inflammation and/or infection, and any substance
that can inhibit this protease results in an anti-inflammatory
effect (22). a1-protease inhibitor (a1-PI) and ulinastatin are
intrinsic physiologic protease inhibitors that suppress PMNE
activity. In inflammatory tissues, a1-PI loses its ability to func-
tion in acidic conditions, but ulinastatin can continue to inhib-
it PMNE (23). In addition, ulinastatin protects endothelial
cells against neutrophil-mediated injury not only by inacti-
vating the extracellular elastase secreted by neutrophils, but
also by acting directly on neutrophils and suppressing the
production and secretion of activated elastase (13). 
Toth et al. (18) reported that ALT was suppressed by two
thirds after injecting anti-IL-6 in resuscitated rats with hep-
atic injury from trauma-induced hemorrhagic shock. Vallejo
et al. (24) found that treatment with a TNF-a receptor antag-
onist abrogated inflammatory mediators and left ventricular
dysfunction before hemorrhagic shock or at the time of resus-
citation.
Ulinastatin has demonstrated its effectiveness in animal
models of experimentally induced septic and hemorrhagic
shock (9, 14). In a septic shock canine model, ulinastatin im-
proved blood pressure and lactic acid levels. Interestingly,
although ulinastatin does not have anti-microbial activity,
the ulinastatin-treated group was found to have a bacterial
count that was significantly decreased and a higher survival
rate (14). It is thought that ulinastatin might activate the
reticuloendothelial system and phagocytosis (14). In hemor-
rhagic shock, the protective effects of ulinastatin might be
associated with the up-regulation of Bcl-2, an inhibitor of
the cell apoptosis (8). 
Based on the literature, we hypothesized that ulinastatin
would inhibit inflammatory cytokines such as TNF-a, IL-6
and PMNE, but in actuality, we found no differences among
the averages of TNF-a, IL-6 and PMNE concentrations ex-
cept for PMNE on the second day of hospitalization.
Aosasa et al. (6) reported that ulinastatin decreased the
TNF-a production of lipopolysaccharide (LPS)-stimulated
monocytes, but that decrease was not statistically significant.
Serum TNF-a concentrations were low when ulinastatin was
used before LPS stimulation and the serum concentration of
TNF-a was inversely proportional to the amount of ulinas-
tatin. In this study, after ulinastatin was injected in the uli-
nastatin group, the serum TNF-a levels were lower than ini-
tial serum TNF-a levels. Nonetheless, serum TNF-a concen-
trations in the control group increased until the third hospi-
talized day.
Serum IL-6 concentrations decreased by half after one day
of ulinastatin injections in the ulinastatin group. Nishiyama
et al. (5) proposed that ulinastatin might inhibit blood trans-
fusion-induced increases of serum PMNE concentrations but
not IL-6 after laparotomy. In their study, serum PMNE lev-
els increased to a lesser extent than the control group by 50
percent. Tani et al. (15) used a total of 1,500,000 IU of uli-
nastatin for five days after laparotomy. In control and urinary
trypsin inhibitor (UTI) groups, the rate of PMNE produc-
tion per one leukocyte was not significantly different until
the third day of postoperation but it was significantly lower
in the UTI group than in the control group at fifth day. In
another study, laparotomy was performed and ulinastatin was
administered to the patients at the same time. In this instance,
although serum PMNE levels did not decrease significantly,
coagulation and fibrinolysis was significantly inhibited (16).
The reference range of serum PMNE levels was reported
to be 20-180 mg/L (25) or 21-165 mg/L (5). We did not check
the normal serum concentration of PMNE in our study, but
the reference range was 0.15-3.0 ng/mL. The lowest value
was 1.49 ng/mL and the highest value was 19.88 ng/mL. In
clinical studies of the effects after laparotomy or blood trans-
fusion, the peak values of serum PMNE were seen immedi-
ately after operations or blood transfusions. The serum con-
centrations of PMNE was significantly lower in the ulinas-
tatin administration patients with gasterctomy and blood
transfusion, but ulinastatin administration was not seen to
decrease serum concentrations of PMNE (5). In another study,
ulinastatin was not shown to decrease serum PMNE levels,
but the activation of coagulation and fibrinolysis in abdom-
inal surgery was inhibited (16). In this study, serum PMNE
levels increased more than two-fold on the second hospital-
ized day within the control group. In addition, serum IL-6
values were highest upon admission to the ER and then grad-
ually decreased in the ulinastatin group; however in the con-
trol group, serum IL-6 levels after one day of hospitalization
were at their highest value and then subsequently decreased.
In the rat experiment of hemorrhagic shock serum IL-6 con-
centrations increased until 24 hr after shock (18), as the serum
IL-6 level at 24 hr was the highest in the control group in
our study. 
The laboratory data, SIRS, MODS and APACHE III scores,
and mortality rates were not different between the two gro-
ups. This may be due to the small sample size. It may also
be because the control group ultimately underwent the same
medical procedures as the ulinastatin group, including blood
transfusions, fluid therapy, and surgery. Therefore, our study
should be replicated using a larger sample size and a longer
period for clinical study. Furthermore, studies examining vari-
ous dosages of ulinastatin for traumatic hemorrhagic shock
patients are warranted.
It is suggested that ulinastatin treatment could decrease
the serum PMNE levels in trauma patients with hemorrhagic
shock at 48 hr after treatment. As mentioned previously, for
the more positive results, a larger sample size, a longer period
and other dosages of ulinastatin treatment studies are needed.134 K.H. Park, K.H. Lee, H. Kim, et al.
REFERENCES
1. Brun-Buisson C. The epidemiology of the systemic inflammatory
response. Intensive Care Med 2000; 26 (Suppl 1): S64-74.
2. Maitra SR, Gestring M, el-Maghrabi MR. Alternations in hepatic 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase and glucose-6-
phosphatase gene expression after hemorrhagic hypotension and
resuscitation. Shock 1997; 8: 385-8.
3. Lee CC, Marill KA, Carter WA, Crupi RS. A current concept of trau-
ma-induced multiorgan failure. Ann Emerg Med 2001; 38: 170-6.
4. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma
JV, Lambris JD, Ward PA. Protective effects of IL-6 blockade in sep-
sis are linked to reduced c5a receptor expression. J Immunol 2003;
170: 503-7.
5. Nishiyama T, Hanaoka K. Do the effects of a protease inhibitor, uli-
nastatin, on elastase release by blood transfusion depend on inter-
leukin 6? Crit Care Med 2001; 29: 2106-10.
6. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto
A. Mechanism of the inhibitory effect of protease inhibitor on tumor
necrosis factor a production of monocytes. Shock 2001; 15: 101-5.
7. Sato Y, Ishikawa S, Otaki A, Takahashi T, Hasegawa Y, Suzuki M,
Yamagishi T, Morishita Y. Induction of acute-phase reactive sub-
stances during open-heart surgery and efficacy of ulinastatin. Inhibit-
ing cytokines and postoperative organ injury. Jpn J Thorac Cardio-
vasc Surg 2000; 48: 428-34.
8. Chen CC, Liu ZM, Wang HH, He W, Wang Y, Wu WD. Effect of
ulinastatin on renal ischemia-reperfusion injury in rats. Acta Phar-
macol Sin 2004; 25: 1334-40. 
9. Ohnishi H, Suzuki K, Niho T, Ito C, Yamaguchi K. Protective effects
of urinary trypsin inhibitor in experimental shock. Jpn J Pharmacol
1985; 39: 137-44.
10. Fries E, Blom AM. Bikunin-not just a plasma proteinase inhibitor.
Int J Biochem Cell Biol 2000; 32: 125-37.
11. Pugia MJ, Lott JA. Pathophysiology and diagnostic value of urinary
trypsin inhibitors. Clin Chem Lab Med 2005; 43: 1-16.
12. Yano T, Anraku S, Nakayama R, Ushijima K. Neuroprotective effect
of urinary trypsin inhibitor against focal cerebral ischemia-reperfu-
sion injury in rats. Anesthesiology 2003; 98: 465-73.
13. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I. Inhi-
bitory effect of serine protease inhibitors on neutrophil-mediated
endothelial cell injury. J Leukoc Biol 2001; 69: 241-7.
14. Tani T, Aoki H, Yoshioka T, Lin KJ, Kodama M. Treatment of sep-
tic shock with a protease inhibitor in a canine model: a prospective,
randomized, controlled trial. Crit Care Med 1993; 21: 925-30.
15. Tani T, Abe H, Endo Y, Hanasawa K, Kodama M. Effects of a uri-
nary trypsin inhibitor on acute circulatory insufficiency after surgi-
cal operation. Am J Surg 1998; 175: 142-5.
16. Nishiyama T, Yokoyama T, Yamashita K. Effects of a protease inhi-
bitor, ulinastatin, on coagulation and fibrinolysis in abdominal sur-
gery. J Anesth 2006; 20: 179-82.
17. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420:
885-91.
18. Toth B, Yokoyama Y, Schwacha MG, George RL, Rue LW 3rd,
Bland KI, Chaudry IH. Insights into the role of interleukin-6 in the
induction of hepatic injury after trauma-hemorrhagic shock. J Appl
Physiol 2004; 97: 2184-9.
19. Witthaut R, Busch C, Fraunberger P, Walli A, Seidel D, Pilz G, Stutt-
mann R, Speichermann N, Verner L, Werdan K. Plasma atrial natri-
uretic peptide and brain natriuretic peptide are increased in septic
shock: impact of interleukin-6 and sepsis associated left ventricular
dysfunction. Intensive Care Med 2003; 29: 1696-702.
20. Duswald KH, Jochum M, Schramm W, Fritz H. Released granulo-
cytic elastase: an indicator of pathobiochemical alterations in sep-
ticemia after abdominal surgery. Surgery 1985; 98: 892-9.
21. Pacholok SG, Davies P, Dorn C, Finke P, Hanlon WA, Mumford
RA, Humes JL. Formation of polymorphonuclear leukocyte elastase:
alpha 1 proteinase inhibitor complex and A alpha (1-21) fibrinopep-
tide in human blood stimulated with the calcium ionophore A23187.
A model to characterize inhibitors of polymorphonuclear leukocyte
elastase. Biochem Pharmacol 1995; 49: 1513-20.
22. Mania-Pramanik J, Potdar SS, Vadigoppula A, Sawant S. Elastase:
a predictive marker of inflammation and/or infection. J Clin Lab Anal
2004; 18: 153-8.
23. Ogawa M, Nishibe S, Mori T, Neumann S. Effect of human urinary
trypsin inhibitor on granulocyte elastase activity. Res Commun Chem
Pathol Pharmacol 1987; 55: 271-4.
24. Vallejo JG, Nemoto S, Ishiyama M, Yu B, Knuefermann P, Diwan
A, Baker JS, Defreitas JS, Tweardy DJ, Mann DL. Functional signifi-
cance of inflammatory mediators in a murine model of resuscitated
hemorrhagic shock. Am J Physiol Heart Circ Physiol 2005; 288:
H1272-7. 
25. Neumann S, Gunzer G, Hennrich N, Lang H. ‘‘PMN-elastase assay’’:
enzyme immunoassay for human polymorphonuclear elastase com-
plexed with alpha 1-proteinase inhibitor. J Clin Chem Clin Biochem
1984; 22: 693-7. 